Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

AUSL Romagna Rimini

Status: Terminated

Conditions: COVID-19

Treatments: Drug: Canakinumab 150 MG/ML [Ilaris]

Study type: Observational

Funder types: Other

Identifiers

NCT04348448

CANASCOV

Details and patient eligibility

About

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Enrollment: 100 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously
• Age> 18 years
• Pneumonia diagnosed with Chest X-ray / or Chest CT

Exclusion criteria

• Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)